Cargando…
Gas6 in chronic liver disease—a novel blood-based biomarker for liver fibrosis
The expression of the receptor tyrosine kinase Axl and its cleavage product soluble Axl (sAxl) is increased in liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). In this multicenter study, we evaluated the diagnostic value of Gas6, the high-affinity ligand of Axl, in patients with chroni...
Autores principales: | Staufer, Katharina, Huber, Heidemarie, Zessner-Spitzenberg, Jasmin, Stauber, Rudolf, Finkenstedt, Armin, Bantel, Heike, Weiss, Thomas S., Huber, Markus, Starlinger, Patrick, Gruenberger, Thomas, Reiberger, Thomas, Sebens, Susanne, McIntyre, Gail, Tabibiazar, Ray, Giaccia, Amato, Zoller, Heinz, Trauner, Michael, Mikulits, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397215/ https://www.ncbi.nlm.nih.gov/pubmed/37532736 http://dx.doi.org/10.1038/s41420-023-01551-6 |
Ejemplares similares
-
Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis
por: Dengler, Mirko, et al.
Publicado: (2017) -
The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis
por: Staufer, Katharina, et al.
Publicado: (2017) -
Immunological Aspects of AXL/GAS‐6 in the Context of Human Liver Regeneration
por: Ortmayr, Gregor, et al.
Publicado: (2021) -
Qualitätssicherung in der Vorsorgekoloskopie in Österreich und europaweit
por: Zessner-Spitzenberg, Jasmin, et al.
Publicado: (2022) -
Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500
por: Bonifacio, Laura, et al.
Publicado: (2019)